Mark Daly, PhD, was appointed Director of the Institute for Molecular Medicine Finland (FIMM) in February 2018. He retains also his affiliations in Boston at the Harvard Medical School, Massachusetts General Hospital and as an institute member of the Broad Institute and co-director of the Program in Medical and Population Genetics.
Daly received his B.S. in physics from the Massachusetts Institute of Technology and his Ph.D. in human genetics from Leiden University, Netherlands. He received the Curt Stern Award from the American Society of Human Genetics in 2014 and was elected to the National Academy of Medicine
in 2017. In 2019 he was awarded Aarhus University’s Honorary Doctorate at the Faculty of Health. His research primarily focuses on the development and application of statistical methods for the discovery and interpretation of genetic variation responsible for complex human disease. In addition to foundational work in human genetics methodology, his lab has made major contributions to gene
discovery in inflammatory bowel disease, autism and schizophrenia – primarily through catalyzing global collaborative research efforts which he continues to help lead. He is a co-architect of the FinnGen project, a landmark public-private effort to integrate decades of medical registry data with genomic data in 10% of the Finnish population.
Dr Daly coordinates the leadership team of the COVID-19 Host Genetics Initiative (HGI) (https://www.covid19hg.org). The purpose of the initiative is to bring together the human genetics research community to generate, share, and analyse data to define the genetic determinants of COVID-19 susceptibility, severity, and outcomes.
Mark Daly is an author of 478 peer-reviewed manuscripts (PubMed 8/2020) with a total of more than 290,000 citations, has an h-index of 201 (Google scholar 8/2020), and has been listed by Thompson ISI/Science Watch in 2008 and 2010 as one of the top ten authors ranked by number of high-impact papers.
Tuesday 01 June